Revenue
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Inc. (FHTX)
Price$4.92Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430,000 | — |
| Research & development | $85.5M | $94.5M | $109.7M | $105.6M | $80.3M | $57.7M | $44.4M |
| Operating expenses | $117.3M | $125.3M | $142.1M | $136.4M | $102.1M | $69.0M | $51.1M |
| Operating income | −$86.4M | −$102.7M | −$107.9M | −$117.1M | −$100.7M | −$68.5M | −$51.1M |
| Operating margin | −279.49% | −454.31% | −315.93% | −609.20% | −7,637.15% | −15,937.44% | — |
| EBITDA | −$83.1M | −$99.6M | −$104.5M | −$113.8M | −$97.5M | −$67.2M | −$50.4M |
| EBITDA margin | −268.71% | −440.51% | −305.83% | −591.93% | −7,392.49% | −15,628.84% | — |
| Net income | −$74.3M | −$86.6M | −$98.4M | −$108.9M | −$101.3M | −$68.8M | −$51.1M |
| Net profit margin | −240.33% | −383.24% | −288.17% | −566.27% | −7,681.58% | −16,000.00% | — |
| Basic EPSper basic share | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | -$12.20 |
| Diluted EPSper diluted share | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | -$12.20 |
Owners
Reported shareholders
21.59%of listed shares
Flagship Pioneering, LLC12.67M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Flagship Pioneering, LLC | 21.59%12.67M shares |
BVF INC/IL | 9.95%5.84M shares |
FMR LLC | 9.72%5.71M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 7.48%4.39M shares |
BlackRock, Inc. | 4.47%2.63M shares |
RAYMOND JAMES FINANCIAL INC | 4.24%2.49M shares |
Euclidean Capital LLC | 2.68%1.57M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.55%1.49M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.55%910.87K shares |
Siren, L.L.C. | 1.23%720.72K shares |
STATE STREET CORP | 1.19%697.47K shares |
AMERIPRISE FINANCIAL INC | 0.95%558.69K shares |
GOTTSCHALK ADRIAN | ≈0.87%511.7K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.64%377.94K shares |
Candriam S.C.A. | 0.53%313.77K shares |
NORTHERN TRUST CORP | 0.53%309.78K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 0.52%305.43K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.52%304.43K shares |
Birchview Capital, LP | 0.48%281.94K shares |
VANGUARD FIDUCIARY TRUST CO | 0.45%264.42K shares |
Percentages use 58.71M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 23, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 857 | $10.17 | $8.7K | 0 |
| Sep 20, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 35.8K | $10.04 | $359.0K | 0 |
| Sep 18, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 11.6K | $10.05 | $116.3K | 0 |
| Sep 17, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 10.3K | $10.04 | $103.1K | 0 |
| Sep 16, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 400 | $10.00 | $4.0K | 0 |